Hartl, Lukas
Jachs, Mathias
Desbalmes, Christopher
Schaufler, Dunja
Simbrunner, Benedikt
Paternostro, Rafael
Schwabl, Philipp
Bauer, David Josef Maria
Semmler, Georg
Scheiner, Bernhard
Bucsics, Theresa
Eigenbauer, Ernst
Marculescu, Rodrig
Szekeres, Thomas
Peck-Radosavljevic, Markus
Kastl, Stefan
Trauner, Michael
Mandorfer, Mattias
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Gilead Sciences (2018-FA716E0930)
Medical University of Vienna
Article History
Received: 15 January 2021
Accepted: 30 April 2021
First Online: 21 May 2021
Declarations
:
: L.H., M.J., C.D., D.S., R.P., G.S., E.E., R.M., T.S. and S.K. declare no conflict of interest. B.Simbrunner received travel support from AbbVie and Gilead. P.S. received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk. D.B. has received travel support from AbbVie and Gilead. B.Scheiner received travel support from Gilead, AbbVie and Ipsen. T.B. received travel support from AbbVie, Bristol-Myers Squibb, and Medis, as well as speaker fees from Bristol-Myers Squibb. M.P.-R. served as investigator for Abbott, Arqle-Daiichi, Bayer, BMS, Boehringer-Ingelheim, Gilead, Imclone, Ipsen, Novartis and Roche, as a speaker and/or advisor for Abbott, Bayer, BMS, Boehringer-Ingelheim, Eisai, Gilead, Ipsen, MSD and Roche, received grant support from Abbott, Bayer, Gilead, MSD and Roche; data and safety monitoring board: BMS, Lilly-Imclone, ONXEO. M.T. received grant support from Albireo, Cymabay, Falk, Gilead, Intercept, MSD, and Takeda, honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, and 3Regulus, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept and MSD, as well as travel support from AbbVie, FalkGilead and Intercept. M.M. served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. T.R. received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche.
: The study was approved by the ethics committee (EC) of the Medical University of Vienna (1493/2016) and performed according to the current version of the Helsinki Declaration. Due to the retrospective design of the study the EC waived the need for informed consent.